Cited by 1,249Cancer Immunotherapy and BiomarkersChromatin Remodeling and CancerRenal cell carcinoma treatment

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Open access

Miao, Diana, Margolis, Claire A., Gao, Wenhua, Voss, Martin H., Li, Wei, Martini, Dylan J., Norton, Craig, Bossé, Dominick, Wankowicz, Stephanie M., Cullen, Dana, Horak, Christine, Wind-Rotolo, Megan, Tracy, Adam, Giannakis, Marios, Hodi, Frank Stephen, Drake, Charles G., Ball, Mark W., Allaf, Mohamad E., Snyder, Alexandra, Hellmann, Matthew D., Ho, Thai, Motzer, Robert J., Signoretti, Sabina, Kaelin, William G., Choueiri, Toni K., Van Allen, Eliezer M.·2018·Science

DOI 10.1126/science.aan5951PMC PMC6035749

Open this paper in CoChat — free account

Abstract

SNF'ing out antitumor immunity: Immune checkpoint inhibitors induce durable tumor regressions in some, but not all, cancer patients. Understanding the mechanisms that determine tumor sensitivity to these drugs could potentially expand the number of patients who benefit (see the Perspective by Ghorani and Quezada). Pan et al. discovered that tumor cells in which a specific SWI/SNF chromatin remodeling complex had been experimentally inactivated were more sensitive to T cell–mediated killing. The cells were more responsive to interferon-γ, leading to increased secretion of cytokines that promote antitumor immunity. Miao et al. examined the genomic features of tumors from patients with metastatic renal cell carcinoma who had been treated with immune checkpoint inhibitors. Tumors harboring inactivating mutations in PBRM1 , which encodes a subunit of the same SWI/SNF complex, were more likely to respond to the drugs. Science , this issue p. 770 , p. 801 ; see also p. 745

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/science.aan5951

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658

Show all 57 references

Sorted by citations

Items 301–400 of 1,001

Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states
Nyman, J., Denize, T., Bakouny, Z., Labaki, C., Titchen, B. M., Bi, K., Hari, S. N., Rosenthal, J., Mehta, N., Jiang, B., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101189 · Cited by 43
Self-citation
Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers
Chabanon, R. M., Morel, D., & Postel-Vinay, S. C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.018 · Cited by 44
Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Martini, D. J., Goyal, S., Liu, Y., Evans, S. T., Olsen, T. A., Case, K. B., Magod, B. L., Brown, J. T., Yantorni, L. B., Russler, G. A., et al. (2021) · The Oncologist · doi:10.1002/onco.13868 · Cited by 43
Self-citation
Emerging Biomaterials Imaging Antitumor Immune Response
Ma, X., Zhang, M., Wang, J., Zhang, T., Xue, P., Kang, Y., Sun, Z., & Xu, Z. (2022) · Advanced Materials · doi:10.1002/adma.202204034 · Cited by 42
MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights
Simonaggio, A., Ambrosetti, D., Verkarre, V., Auvray, M., Oudard, S. M., & Vano, Y. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147649 · Cited by 44
Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors
Burgers, F. H., van der Mijn, J. C., Seijkens, T. T. P., Jedema, I., Bex, A., & Haanen, J. B. A. G. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00983-w · Cited by 49
An Update on Predictive Biomarkers in Metastatic Renal Cell Carcinoma
Dudani, S., Savard, M.-F., & Heng, D. Y. C. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.04.004 · Cited by 42
HIF1A expression correlates with increased tumor immune and stromal signatures and aggressive phenotypes in human cancers
Chen, B., Li, L., Li, M., & Wang, X. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00534-4 · Cited by 41
Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma
Xu, W., Ma, C., Liu, W., Anwaier, A., Tian, X., Shi, G., Qu, Y., Wei, S., Zhang, H., & Ye, D. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03123-y · Cited by 42
Pan‐cancer analysis reveals sex‐specific signatures in the tumor microenvironment
Han, J., Yang, Y., Li, X., Wu, J., Sheng, Y., Qiu, J., Wang, Q., Li, J., He, Y., Cheng, L., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13203 · Cited by 43
IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma
Rizzo, M., Varnier, L., Pezzicoli, G., Pirovano, M., Cosmai, L., & Porta, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.990568 · Cited by 48
Clear cell renal cell carcinoma with wild‐type von Hippel‐Lindau gene: a non‐existent or new tumour entity?
Batavia, A. A., Schraml, P., & Moch, H. (2018) · Histopathology · doi:10.1111/his.13749 · Cited by 42
Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma
Labriola, M., Batich, K. A., Zhu, J., McNamara, M. A., Harrison, M. R., Armstrong, A. J., George, D. J., & Zhang, T. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.01.017 · Cited by 41
Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules
Wang, Z., Li, K., Chen, W., Wang, X., Huang, Y., Wang, W., Wu, W., Cai, Z., & Huang, W. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03362-4 · Cited by 40
The roles of mutated SWI/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: A review
Hu, B., Lin, J., Yang, X., & Sang, X. (2020) · Cell Proliferation · doi:10.1111/cpr.12791 · Cited by 40
CRISPR screen in mechanism and target discovery for cancer immunotherapy
Liu, D., Zhao, X., Tang, A., Xu, X., Liu, S., Zha, L., Ma, W., Zheng, J., & Shi, M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188378 · Cited by 44
Integrative radiogenomics analysis for predicting molecular features and survival in clear cell renal cell carcinoma
Zeng, H., Chen, L., Wang, M., Luo, Y., Huang, Y., & Ma, X. (2021) · Aging · doi:10.18632/aging.202752 · Cited by 40
Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis
Li, S., Noor, Z. S., Zeng, W., Stackpole, M. L., Ni, X., Zhou, Y., Yuan, Z., Wong, W. H., Agopian, V. G., Dubinett, S. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24457-2 · Cited by 41
Self-citation
Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
Nishio, S., Matsumoto, K., Takehara, K., Kawamura, N., Hasegawa, K., Takeshima, N., Aoki, D., Kamiura, S., Arakawa, A., Kondo, E., et al. (2020) · Cancer Science · doi:10.1111/cas.14340 · Cited by 40
ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma
Fukumoto, T., Lin, J., Fatkhutdinov, N., Liu, P., Somasundaram, R., Herlyn, M., Zhang, R., & Nishigori, C. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.11.026 · Cited by 40
Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies
Guillaume, Z., Auvray, M., Vano, Y. A., Oudard, S. M., Helley, D., & Mauge, L. (2022) · Cancers · doi:10.3390/cancers14246167 · Cited by 48
Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution
Thol, K., Pawlik, P., & McGranahan, N. (2022) · Genome Medicine · doi:10.1186/s13073-022-01138-3 · Cited by 47
Secreted phosphoprotein 1 as a potential prognostic and immunotherapy biomarker in multiple human cancers
Zeng, P., Zhang, X., Xiang, T., Ling, Z., Lin, C., & Diao, H. (2022) · Bioengineered · doi:10.1080/21655979.2021.2020391 · Cited by 39
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma
Jammihal, T., Saliby, R. M., Labaki, C., Soulati, H., Gallegos, J., Peris, A., McCurry, D., Yu, C., Shah, V., Poduval, D., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00896-w · Cited by 38
Self-citation
Characteristics and prognostic value of potential dependency genes in clear cell renal cell carcinoma based on a large-scale CRISPR-Cas9 and RNAi screening database DepMap
Shi, B., Ding, J., Qi, J., & Gu, Z. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.51703 · Cited by 39
Management of Renal Cell Carcinoma: Promising Biomarkers and the Challenges to Reach the Clinic
Lyskjær, I., Iisager, L., Axelsen, C. T., Nielsen, T. K., Dyrskjøt, L., & Fristrup, N. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1892 · Cited by 38
PBRM1 Regulates Stress Response in Epithelial Cells
Porter, E. G. P., Dhiman, A., Chowdhury, B., Carter, B. C., Lin, H., Stewart, J. C., Kazemian, M., Wendt, M. K., & Dykhuizen, E. C. (2019) · iScience · doi:10.1016/j.isci.2019.04.027 · Cited by 37
Pbrm1 Steers Mesenchymal Stromal Cell Osteolineage Differentiation by Integrating PBAF-Dependent Chromatin Remodeling and BMP/TGF-β Signaling
Sinha, S., Biswas, M., Chatterjee, S. S., Kumar, S., & Sengupta, A. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107570 · Cited by 38
CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
Zhou, Q., Qi, Y., Wang, Z., Zeng, H., Zhang, H., Liu, Z., Huang, Q., Xiong, Y., Wang, J., Chang, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000228 · Cited by 38
Stem Cell Theory of Cancer: Origin of Tumor Heterogeneity and Plasticity
Tu, S., Zhang, M., Wood, C. G., & Pisters, L. L. (2021) · Cancers · doi:10.3390/cancers13164006 · Cited by 40
Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
Iinuma, K., Enomoto, T., Kawada, K., Fujimoto, S., Ishida, T., Takagi, K., Nagai, S., Ito, H., Kawase, M., Nakai, C., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10225325 · Cited by 40
MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer
Hagiwara, M., Fushimi, A., Bhattacharya, A., Yamashita, N., Morimoto, Y., Oya, M., Withers, H. G., Hu, Q., Liu, T., Liu, S., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2029298 · Cited by 37
Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma
Freeman, S. S., Sade-Feldman, M., Kim, J., Stewart, C., Gonye, A. L. K., Ravi, A., Arniella, M. B., Gushterova, I., LaSalle, T. J., Blaum, E. M., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100500 · Cited by 41
Development and validation of a prognostic model for kidney renal clear cell carcinoma based on RNA binding protein expression
Xiang, Y., Zhou, S., Hao, J., Zhong, C., Ma, Q., Sun, Z., & Wei, C. (2020) · Aging · doi:10.18632/aging.104137 · Cited by 35
Targeting SWI/SNF Complexes in Cancer: Pharmacological Approaches and Implications
Dreier, M. R., Walia, J., & de la Serna, I. L. (2024) · Epigenomes · doi:10.3390/epigenomes8010007 · Cited by 39
Personalized Management of Advanced Kidney Cancer
Graham, J., Heng, D. Y. C., Brugarolas, J., & Vaishampayan, U. N. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201215 · Cited by 37
Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer
Liao, L., Liu, Z. Z., Langbein, L. E., Cai, W., Cho, E.-A., Na, J., Niu, X., Jiang, W., Zhong, Z., Cai, W. L., et al. (2018) · eLife · doi:10.7554/elife.37925 · Cited by 39
Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment
Siu, E. H.-L., Chan, A. W. H., Chong, C. C. N., Chan, S. L., Lo, K. W., & Cheung, S. (2018) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2018.10.16 · Cited by 37
Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury
Williamson, L. M., Rive, C. M., Francesco, D. D., Titmuss, E., Chun, H.-J. E., Brown, S. D., Milne, K., Pleasance, E., Lee, A. F., Yip, S. S. F., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00238-4 · Cited by 38
PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients
Denize, T., Jegede, O. A., Matar, S., Ahmar, N. E., West, D. J., Walton, E., Bagheri, A. S., Savla, V., Laimon, Y. N., Gupta, S., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2274 · Cited by 36
Self-citation
Intratumoral mycobiome heterogeneity influences the tumor microenvironment and immunotherapy outcomes in renal cell carcinoma
Mou, W., Deng, Z., Zhu, L., Jiang, A., Lin, A., Xu, L., Deng, G., Huang, H., Guo, Z., Zhu, B., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu1727 · Cited by 36
Refining patient selection for breast cancer immunotherapy: beyond PD-L1
Kossai, M., Radosevic-Robin, N., & Penault-Llorca, F. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100257 · Cited by 36
Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma
Gulati, S., Barata, P. C., Elliott, A., Bilen, M. A., Burgess, E. F., Choueiri, T. K., Darabi, S., Dawson, N. A., Gartrell, B. A., Hammers, H. J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176230 · Cited by 35
Self-citation
Advances in theranostic biomarkers for tumor immunotherapy
Bellesœur, A., Torossian, N., Amigorena, S., & Romano, E. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.02.005 · Cited by 34
Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway
Stransky, L. A., Vigeant, S. M., Huang, B., West, D. J., Denize, T., Walton, E., Signoretti, S., & Kaelin, W. G. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2120403119 · Cited by 36
Self-citation
Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model
Zheng, K. C., Hai, Y., Chen, H., Zhang, Y., Hu, X., & Ni, K. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05186-8 · Cited by 36
Tracing Renal Cell Carcinomas back to the Nephron
Lindgren, D., Sjölund, J., & Axelson, H. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.05.003 · Cited by 40
High affinity binding of H3K14ac through collaboration of bromodomains 2, 4 and 5 is critical for the molecular and tumor suppressor functions of PBRM 1
Liao, L., Alicea‐Velázquez, N. L., Langbein, L. E., Niu, X., Cai, W., Cho, E., Zhang, M., Greer, C. B., Yan, Q., Cosgrove, M. S., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12434 · Cited by 34
PD-L1 Regulates Inflammation in LPS-Induced Lung Epithelial Cells and Vascular Endothelial Cells by Interacting with the HIF-1α Signaling Pathway
Zhao, S., Gao, J., Li, J., Wang, S., Yuan, C., & Liu, Q. (2021) · Inflammation · doi:10.1007/s10753-021-01474-3 · Cited by 34
Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors
Martini, D. J., Shabto, J. M., Goyal, S., Liu, Y., Olsen, T. A., Evans, S. T., Magod, B. L., Ravindranathan, D., Brown, J. T., Yantorni, L. B., et al. (2021) · The Oncologist · doi:10.1002/onco.13922 · Cited by 36
Self-citation
Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers
McGrail, D. J., Pilie, P. G., Dai, H., Lam, T., Liang, Y., Voorwerk, L., Kok, M., Zhang, X. H.-F., Rosen, J. M., Heimberger, A. B., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe6201 · Cited by 36
The potential value of cuprotosis (copper-induced cell death) in the therapy of clear cell renal cell carcinoma
Qi, X. (2022) · American Journal of Cancer Research · doi:10.62347/etjh6697 · Cited by 34
MHC II immunogenicity shapes the neoepitope landscape in human tumors
Kim, J. Y., Cha, H., Kim, K., Sung, C., An, J., Bang, H., Kim, H., Yang, J. O., Chang, S., Shin, I., et al. (2023) · Nature Genetics · doi:10.1038/s41588-022-01273-y · Cited by 33
Summary From the First Kidney Cancer Research Summit, September 12–13, 2019: A Focus on Translational Research
Choueiri, T. K., Atkins, M. B., Bakouny, Z., Carlo, M. I., Drake, C. G., Jonasch, E. W., Kapur, P., Lewis, B., Linehan, W. M., Mitchell, M. J., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa064 · Cited by 33
Self-citation
Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
Bai, J., Shi, J., Zhang, Y., Li, C., Xiong, Y., Koka, H., Wang, D., Zhang, T., Song, L., Luo, W., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1865 · Cited by 33
Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens
Wolf, M. M., Rathmell, W. K., & de Cubas, A. A. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00700-5 · Cited by 38
Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy
Lee, J., & Kim, E. H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1233376 · Cited by 36
Robust identification of perturbed cell types in single-cell RNA-seq data
Nicol, P. B., Paulson, D., Qian, G., Liu, X. S., Irizarry, R. A., & Sahu, A. D. (2024) · Nature Communications · doi:10.1038/s41467-024-51649-3 · Cited by 35
Recent advances in the biology of tumour hypoxia with relevance to diagnostic practice and tissue‐based research
Macklin, P. S., Yamamoto, A., Browning, L., Hofer, M., Adam, J., & Pugh, C. W. (2020) · The Journal of Pathology · doi:10.1002/path.5402 · Cited by 33
Ferroptosis-associated molecular classification characterized by distinct tumor microenvironment profiles in colorectal cancer
Luo, W., Dai, W., Li, Q., Mo, S., Han, L., Xiao, X., Gu, R., Xiang, W., Ye, L., Wang, R., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.69808 · Cited by 34
Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation
Zhu, L., Kuang, X., Zhang, G., Liang, L., Liu, D., Hu, B., Xie, Z., Li, H., Liu, H., Ye, M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003819 · Cited by 33
Understanding the Tumor Immune Microenvironment in Renal Cell Carcinoma
Shapiro, D. D., Dolan, B. K., Laklouk, I. A., Rassi, S., Ložar, T., Emamekhoo, H., Wentland, A. L., Lubner, M. G., & Abel, E. J. (2023) · Cancers · doi:10.3390/cancers15092500 · Cited by 35
SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors
Panwalkar, P., Pratt, D. W., Chung, C., Dang, D., Le, P., Martínez, D., Bayliss, J. M., Smith, K. S., Adam, M., Potter, S. S., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa004 · Cited by 32
RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma
Li, H., Hu, J., Yu, A., Othmane, B., Guo, T., Liu, J., Cheng, C., Chen, J., & Zu, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.642159 · Cited by 32
T and NK cell abundance defines two distinct subgroups of renal cell carcinoma
Lee, M. H., Järvinen, P., Nísen, H., Brück, O. E., Ilander, M., Uski, I., Theodoropoulos, J., Kankainen, M., Mirtti, T. K., Mustjoki, S. M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2021.1993042 · Cited by 32
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
Tomlins, S. A., Khazanov, N. A., Bulen, B. J., Hovelson, D. H., Shreve, M. J., Lamb, L. E., Matrana, M. R., Burkard, M. E., Yang, E. S.-H., Edenfield, W. J., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00243-7 · Cited by 30
PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Saxena, M., Marron, T. U., Kodysh, J., Finnigan, J. P., Onkar, S., Kaminska, A., Tuballes, K., Guo, R., Sabado, R. L., Meseck, M., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0934 · Cited by 28
Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review
Rebuzzi, S. E., Perrone, F., Bersanelli, M., Bregni, G., Milella, M., & Buti, S. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1680286 · Cited by 31
Bioinformatics analysis and verification of gene targets for renal clear cell carcinoma
Feng, L., Jin, Y., Pei, X., Guo, P., Dong, K., Wang, H., Chen, Y., Guo, P., Meng, L., & Wang, Z. (2021) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2021.107453 · Cited by 30
Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy
Sun, S., Xu, L., Zhang, X., Pang, L., Long, Z., Deng, C., Zhu, J., Zhou, S., Wan, L., Pang, B., et al. (2021) · Cancers · doi:10.3390/cancers13071639 · Cited by 32
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab
Lee, C., DiNatale, R. G., Chowell, D., Krishna, C., Makarov, V., Valero, C., Vuong, L. H., Lee, M., Weiss, K. L., Hoen, D., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0053 · Cited by 31
Self-citation
Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade
Yoshida, T., Ohe, C., Ikeda, J., Atsumi, N., Ohsugi, H., Sugi, M., Higasa, K., Saito, R., Tsuta, K., Matsuda, T., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002922 · Cited by 31
DEPTH2: an mRNA-based algorithm to evaluate intratumor heterogeneity without reference to normal controls
Song, D., & Wang, X. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03355-1 · Cited by 33
Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy
Krishnamurthy, N., Kato, S., Lippman, S. M., & Kurzrock, R. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004669 · Cited by 31
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses
Friedman, C. F., Manning‐Geist, B. L., Zhou, Q. C., Soumerai, T. E., Holland, A., Paula, A. D. C., Green, H., Ozsoy, M. A., Iasonos, A. E., Hollmann, T. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02942-7 · Cited by 30
Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression
Roerden, M., Castro, A., Cui, Y., Harake, N., Kim, B., Dye, J., Maiorino, L., White, F. M., Irvine, D. J., Litchfield, K., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010249 · Cited by 30
Progress of immune checkpoint therapy in the clinic (Review)
Fan, Y., Zhang, C., Jin, S., Gao, Z., Cao, J., Wang, A., Li, D., Wang, Q., Sun, X., & Bai, D. (2018) · Oncology Reports · doi:10.3892/or.2018.6819 · Cited by 30
Real-World Outcomes of Nivolumab and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Stukalin, I., Wells, J. C., Graham, J., Yuasa, T., Beuselinck, B., Kollmansberger, C. K., Ernst, D. S., Agarwal, N., Le, T., Donskov, F. N., et al. (2019) · Current Oncology · doi:10.3747/co.26.4595 · Cited by 30
Self-citation
Whole-Exome Sequencing Identifies Somatic Mutations Associated With Mortality in Metastatic Clear Cell Kidney Carcinoma
Mendoza-Álvarez, A., Guillén‐Guío, B., Baez‐Ortega, A., Hernandez-Perez, C., Lakhwani-Lakhwani, S., Maeso, M.-D.-C., Lorenzo-Salazar, J. M., Morales, M., & Flores, C. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00439 · Cited by 30
Tumor Milieu Controlled by RB Tumor Suppressor
Kitajima, S., Li, F., & Takahashi, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072450 · Cited by 30
Clonal tracing reveals diverse patterns of response to immune checkpoint blockade
Gu, S. S., Wang, X., Hu, X. S., Jiang, P., Li, Z., Traugh, N. C., Bu, X., Tang, Q., Wang, C., Zeng, Z., et al. (2020) · Genome biology · doi:10.1186/s13059-020-02166-1 · Cited by 29
Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date
Tacconi, E. M., Tuthill, M. H., & Protheroe, A. S. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s174149 · Cited by 30
Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma
Xia, R., Xiao, J., Zhang, Y., Teng, H., Cheng, F., Chen, H., Zhang, K., & Sun, Z. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920977117 · Cited by 30
Tumor Immune Microenvironment Characterization in Hepatocellular Carcinoma Identifies Four Prognostic and Immunotherapeutically Relevant Subclasses
Gao, X., Huang, H., Wang, Y., Pan, C., Yin, S., Zhou, L., & Zheng, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.610513 · Cited by 30
A BAP1 synonymous mutation results in exon skipping, loss of function and worse patient prognosis
Niersch, J., Vega-Rubín-de-Celis, S., Bazarna, A., Mergener, S., Jendrossek, V., Siveke, J. T., & Peña‐Llopis, S. (2021) · iScience · doi:10.1016/j.isci.2021.102173 · Cited by 30
Pan-cancer characterization of lncRNA modifiers of immune microenvironment reveals clinically distinct de novo tumor subtypes
Zhang, Z., Yan, C., Li, K., Bao, S., Li, L., Chen, L., Zhao, J., Sun, J., & Zhou, M. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00215-7 · Cited by 30
The BAF chromatin remodeling complexes: structure, function, and synthetic lethalities
Varga, J., Kube, M., Luck, K., & Schick, S. (2021) · Biochemical Society Transactions · doi:10.1042/bst20190960 · Cited by 31
Comprehensive Analysis of m5C RNA Methylation Regulator Genes in Clear Cell Renal Cell Carcinoma
Wu, J., Hou, C., Wang, Y., Wang, Z., Li, P., & Wang, Z. (2021) · International Journal of Genomics · doi:10.1155/2021/3803724 · Cited by 30
SWI/SNF Complex Genomic Alterations as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Multiple Cancers
Wang, D., Wang, J., Zhou, D., Wu, Z., Liu, W., Chen, Y., Chen, G., & Zhang, J. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0813 · Cited by 32
Geospatial characterization of immune cell distributions and dynamics across the microenvironment in clear cell renal cell carcinoma
Chakiryan, N. H., Kim, Y., Berglund, A., Chang, A. C., Kimmel, G. J., Hajiran, A. J., Nguyen, J. V., Segura, C. M., Saeed‐Vafa, D., Katende, E. N., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006195 · Cited by 29
Current status of prognostic factors in patients with metastatic renal cell carcinoma
Teishima, J., Inoue, S., Hayashi, T., & Matsubara, A. (2019) · International Journal of Urology · doi:10.1111/iju.13956 · Cited by 30
Genetic Alterations in Renal Cancers: Identification of The Mechanisms Underlying Cancer Initiation and Progression and of Therapeutic Targets
Testa, U., Pelosi, E., & Castelli, G. (2020) · Medicines · doi:10.3390/medicines7080044 · Cited by 30
Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy
Halima, A., Vuong, W., & Chan, T. A.-T. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154945 · Cited by 31
Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses
Yan, J., Chen, Y., Patel, A. J., Warda, S., Lee, C. J., Nixon, B. G., Wong, E. W. P., Miranda-Román, M. A., Yang, N., Wang, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153437 · Cited by 30
PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma
Yao, X., Hong, J. H., Nargund, A. M., Ng, M. S. W., Heng, H. L., Li, Z., Guan, P., Sugiura, M., Chu, P. L., Wang, L. C., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01122-y · Cited by 29
Single-cell histone chaperones patterns guide intercellular communication of tumor microenvironment that contribute to breast cancer metastases
Xie, J., Deng, W., Deng, X., Liang, J., Tang, Y., Huang, J. T., Tang, H., Zou, Y., Zhou, H., & Xie, X. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03166-4 · Cited by 29
Determinants of anti-PD1 response and resistance in clear cell renal cell carcinomaPreprint
Au, L., Hatipoglu, E., de Massy, M. R., Litchfield, K., Rowan, A., Thompson, R. H., Schnidrig, D., Byrne, F., Beattie, G., Horswell, S. D., et al. (2021) · medRxiv · doi:10.1101/2021.03.19.21253661 · Cited by 29
Spatially segregated APOE+ macrophages restrict immunotherapy efficacy in clear cell renal cell carcinoma
Ge, Q., Meng, J., Wang, Z., Anwaier, A., Lu, J., Tian, X., Wang, Y., Yang, J., Zhang, H., Ye, D., et al. (2025) · Theranostics · doi:10.7150/thno.109097 · Cited by 29
Heat-Shock Protein 90 Controls the Expression of Cell-Cycle Genes by Stabilizing Metazoan-Specific Host-Cell Factor HCFC1
Антонова, А. В., Hummel, B., Khavaran, A., Redhaber, D. M., Aprile-Garcia, F., Rawat, P., Gundel, K., Schneck, M., Hansen, E. C., Mitschke, J., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.084 · Cited by 27
Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors
Chen, J. A., Ma, W., Yuan, J. D., & Li, T. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_9 · Cited by 29

Authors: Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., Horak, C., Wind-Rotolo, M., Tracy, A., Giannakis, M., Hodi, F. S., Drake, C. G., Ball, M. W., Allaf, M. E., Snyder, A., Hellmann, M. D., Ho, T., Motzer, R. J., Signoretti, S., Kaelin, W. G., Choueiri, T. K., & Van Allen, E. M.
Affiliations: Broad Institute (US)
Dana-Farber Cancer Institute (US)
Memorial Sloan Kettering Cancer Center (US)
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Bristol-Myers Squibb (United States) (US)
Bristol-Myers Squibb, New York, NY 10154, USA.
Columbia University Irving Medical Center (US)
Johns Hopkins University (US)
Mayo Clinic in Arizona (US)
Howard Hughes Medical Institute (US)
Corresponding author: Choueiri, Toni K.
ORCID: Miao, Diana
Margolis, Claire A.
Gao, Wenhua
Voss, Martin H.
Li, Wei
Martini, Dylan J.
Bossé, Dominick
Wind-Rotolo, Megan
Tracy, Adam
Giannakis, Marios
Hodi, Frank Stephen
Drake, Charles G.
Ball, Mark W.
Allaf, Mohamad E.
Snyder, Alexandra
Hellmann, Matthew D.
Ho, Thai
Motzer, Robert J.
Signoretti, Sabina
Kaelin, William G.
Choueiri, Toni K.
Van Allen, Eliezer M.
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2018-02-16
Volume: 359
Issue: 6377
Pages: 801-806
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.aan5951
PMC: PMC6035749
OpenAlex: W2782183686
Cited by: 1,249
References: 57
Citations by year: 2026: 73 · 2025: 93 · 2024: 153 · 2023: 164 · 2022: 186 · 2021: 195 · 2020: 179 · 2019: 113 · 2018: 89
FWCI: 54.48
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: Science (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (K08 CA188615, U24CA224316)
Howard Hughes Medical Institute (Medical Research Fellowship)
American Association for Cancer Research (KureIt Grant for Kidney Research)
NIH Office of the Director (P30 CA008748)
Bristol-Myers Squibb (II-ON Consortium)
Dana-Farber Cancer Institute (Loker Pinard Funds for Kidney Cancer Research)
Dana-Farber/Harvard Cancer Center (Kidney SPORE)
BroadNext10
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Keywords: clear cell renal cell carcinoma, immune checkpoint inhibitors, SWI/SNF complex, PBRM1 mutation, tumor response prediction, antitumor immunity, interferon-gamma, T cell-mediated killing, metastatic renal cell carcinoma, cancer genomics
MeSH terms: Carcinoma, Renal Cell, Chromosomal Proteins, Non-Histone, Humans, Immunotherapy, Kidney Neoplasms, Mutation, Transcription Factors, Cohort Studies, Gene Expression Profiling, Genomics, Exome, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks